Results 11 to 20 of about 36,112 (211)

20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer. [PDF]

PLoS ONE, 2014
Castration-resistant progression of prostate cancer after androgen deprivation therapies remains the most critical challenge in the clinical management of prostate cancer.
Bo Cao, Yanfeng Qi, Yan Yang, Xichun Liu, Duo Xu, Wei Guo, Yang Zhan, Zhenggang Xiong, Allen Zhang, Alun R Wang, Xueqi Fu, Haitao Zhang, Lijing Zhao, Jingkai Gu, Yan Dong   +14 more
doaj   +1 more source

Novel Strategies for Treating Castration-Resistant Prostate Cancer

Biomedicines, 2021
The development of castration resistance is an inevitable pathway for the vast majority of patients with advanced prostate cancer. Recently, there have been significant breakthroughs in the understanding and management options of castration-resistant ...
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh   +3 more
doaj   +1 more source

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high

IJU Case Reports, 2020
Introduction We report the case of a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high who was treated with pembrolizumab after cabazitaxel administration.
Motohiro Fujiwara, Yoshinobu Komai, Takeshi Yuasa, Noboru Numao, Shinya Yamamoto, Iwao Fukui, Junji Yonese   +6 more
doaj   +1 more source

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

IJU Case Reports, 2023
Introduction Transient decrease in serum prostate‐specific antigen level can occur after abiraterone acetate withdrawal in male patient with metastatic castration‐resistant prostate cancer.
Masaru Tani, Yujiro Hayashi, Airi Miki, Teppei Wakita, Yuki Horibe, Yoichi Kakuta, Koichi Tsutahara, Tetsuya Takao   +7 more
doaj   +1 more source

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. [PDF]

PLoS ONE, 2013
Despite advances in detection and therapy, castration-resistant prostate cancer continues to be a major clinical problem. The aberrant activity of stem cell pathways, and their regulation by the Androgen Receptor (AR), has the potential to provide ...
Steven Kregel, Kyle J Kiriluk, Alex M Rosen, Yi Cai, Edwin E Reyes, Kristen B Otto, Westin Tom, Gladell P Paner, Russell Z Szmulewitz, Donald J Vander Griend   +9 more
doaj   +1 more source

A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer

Frontiers in Oncology, 2023
Prostate cancer is the most common cancer in men. About 6% of those diagnosed will develop metastatic disease. Unfortunately, metastatic prostate cancer is fatal. Prostate cancer can be castration sensitive or castration resistant.
Diana V. Maslov, Quinne Sember, Jason Cham, Munveer Bhangoo   +3 more
doaj   +1 more source

Knowledge mapping of immunotherapy in castration-resistant prostate cancer: a bibliometric and visualized study (2003–2022)

Frontiers in Urology, 2023
ObjectiveTo utilize bibliometric analysis to examine the literature about immunotherapy for castration-resistant prostate cancer published within the past two decades.
Xianfu Cai, Xianfu Cai, Chenguang Ding, Yang Li, Jin Zheng, Wujun Xue   +5 more
doaj   +1 more source

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer

IJU Case Reports, 2020
Introduction Cell‐free DNA is suggested as a prognostic biomarker in metastatic castration‐resistant prostate cancer. However, it remains unknown which parameter of cell‐free DNA is correlated with the progression and prognosis of metastatic castration ...
Itsuto Hamano, Shingo Hatakeyama, Tomoko Hamaya, Kyo Togashi, Teppei Okamoto, Hayato Yamamoto, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama   +9 more
doaj   +1 more source

Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer

Scientific Reports, 2023
Prostate cancer is the most prevalent cancer in men worldwide and is promoted by the sex hormone androgen. Expression of androgen from the testis can be significantly reduced through castration.
Won Sik Shin, Seung Hyun Han, Kyung Won Jo, Yunje Cho, Kyong-Tai Kim   +4 more
doaj   +1 more source

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience

Медицинский совет, 2021
Prostate cancer is one of the most common neoplasms in men. It currently ranks second in Russian Federation amongst male population in overall number of cases after only lung cancer and third in cancer mortality.
T. V. Ustinova, L. V. Bolotina, A. A. Paichadze, A. A. Kachmazov, A. A. Fedenko, A. D. Kaprin   +5 more
doaj   +1 more source